Fluorine-18 is the most frequently used radioisotope in positron emission tomography (PET)
radiopharmaceuticals in both clinical and preclinical research. Its physical and nuclear …

In order to accommodate the growing demand for positron emission tomography (PET), it
will be necessary to create innovative radiochemical and engineering technologies to …

Synthesis of non-activated electron-rich and sterically hindered 18F-arenes remains a major
challenge due to limitations of existing radiofluorination methodologies. Herein, we report on …

The hydrogenation of heterocyclic nitroaromatics is of great importance in the
pharmaceutical industry for the synthesis of key intermediates. However, high selectivity is …

Positron emission tomography (PET) is a powerful diagnostic tool that holds incredible
potential for clinicians to track a wide variety of biological processes using specialized …

Zinc, copper, and iron ions are involved in amyloid-beta (Aβ) deposition and stabilization in
Alzheimer's disease (AD). Consequently, metal binding agents that prevent metal-Aβ …

The current utilization of positron emission tomography (PET) imaging is limited due to the
high costs associated with production facility start-up and operations; subsequently, there …

The unique properties of fluorine resulting from its tremendously high electronegativity make
it a key player in the quest of enabling new and advanced qualities for chemical compounds …

The synthesis of fluorine-18 labeled 3-fluoro-5-[(pyridin-3-yl) ethynyl] benzonitrile ([18F]
FPEB) for imaging metabotropic glutamate receptor subtype type 5 (mGluR5) was achieved …

Despite extensive preclinical imaging with radiotracers developed by continuous-flow
microfluidics, a positron emission tomographic (PET) radiopharmaceutical has not been …